Bionas Signs Service Contract with Solvay Pharmaceuticals
Complete the form below to unlock access to ALL audio articles.
Bionas GmbH has announced that it has signed a service contract with Solvay Pharmaceuticals GmbH. The contract covers the metabolic profiling of several drug candidates identified in the context of Solvay´s obesity research program. Financial details were not disclosed.
Solvay has selected the Bionas® 2500 analyzing system because it allows monitoring of both acute (short-term) and chronic (long-term) effects of drug candidates in different cell types thanks to a proprietary perfusion system. Besides the long-term observation of cells under close to in vivo conditions, the observation of regeneration effects is also possible.
"The Bionas instrument is a valuable tool for compound ranking and helps us select the most promising compounds for further development," says Dr. Michael Firnges at Solvay Pharmaceuticals GmbH.
The Bionas® 2500 analyzing system is a bench-top instrument that allows the simultaneous, label-free and high-content analysis of three metabolic parameters, such as acidification, oxygen consumption and adhesion of living cells. The Bionas instrument has been also selected by Solvay Pharmaceuticals Research Laboratories (Weesp, Netherlands) for target validation studies.
